This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Crysvita (burosumab)
General Description:
Crysvita (burosumab) is an injectable therapy indicated for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). It works by targeting and inhibiting excess fibroblast growth factor 23 (FGF23), helping to restore phosphate balance and improve bone health.
Crysvita is administered as an injection under the supervision of a qualified healthcare professional, with dosage and treatment schedules tailored to patient needs.
Getting Crysvita (burosumab) in India
Crysvita can be accessed legally through a Named Patient Program (NPP) in India under the guidance of a licensed physician, as it may not yet be commercially available.
MitoGENE assists Indian patients in obtaining Crysvita safely, handling all regulatory approvals, import permits, and logistics to ensure a secure and compliant process.
Disease Indication:
• X-linked Hypophosphatemia (XLH)
• Tumor-Induced Osteomalacia (TIO)
Manufacturer:
Kyowa Kirin GmbH (Germany)
Usage:
Injection
Available Dosage Form & Package:
• 1 single-dose vial of 10 mg/mL
• 1 single-dose vial of 20 mg/mL
• 1 single-dose vial of 30 mg/mL
Shipping:
Room Temperature Shipping
Crysvita is shipped under controlled room temperature conditions (15–25°C) to maintain stability and effectiveness. Standard shipping procedures ensure the medication remains safe and uncompromised during transit.
How to Access Crysvita (burosumab) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Crysvita (burosumab) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
